Author

Doron Boltin

USE OF PROTON PUMP INHIBITORS IS ASSOCIATED WITH INCREASED RISK OF GASTRIC CANCER IN COMMUNITY DWELLING ELDERLY
USE OF PROTON PUMP INHIBITORS IS ASSOCIATED WITH INCREASED RISK OF GASTRIC CANCER IN COMMUNITY DWELLING ELDERLY

Doron Boltin  et al.

EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Doron Boltin  et al.

ROLE OF MAFB TRANSCRIPTION FACTOR IN HUMAN INTESTINAL METAPLASIA AND GASTRIC CANCER BIOPSIES
ROLE OF MAFB TRANSCRIPTION FACTOR IN HUMAN INTESTINAL METAPLASIA AND GASTRIC CANCER BIOPSIES

Doron Boltin  et al.

DIFFERENT EFFECTS OF CHRONIC OMEPRAZOLE USE ON OSTEOPOROTIC FRACTURES RATE IN THE ELDERS
DIFFERENT EFFECTS OF CHRONIC OMEPRAZOLE USE ON OSTEOPOROTIC FRACTURES RATE IN THE ELDERS

Doron Boltin  et al.

EFFECTS OF TRANSCUTANEOUS ELECTRICAL STIMULATION SYSTEM ON HEARTBURN, REGURGITATION AND ESOPHAGEAL ACID EXPOSURE IN GERD PATIENTS
EFFECTS OF TRANSCUTANEOUS ELECTRICAL STIMULATION SYSTEM ON HEARTBURN, REGURGITATION AND ESOPHAGEAL ACID EXPOSURE IN GERD PATIENTS

Doron Boltin  et al.

EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 2,254 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES
EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 2,254 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES

Doron Boltin  et al.

EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Doron Boltin  et al.

EFFECTIVENESS OF HELICOBACTER PYLORI TREATMENTS ACCORDING TO ANTIBIOTIC RESISTANCE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF HELICOBACTER PYLORI TREATMENTS ACCORDING TO ANTIBIOTIC RESISTANCE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Doron Boltin  et al.

TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021
TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021

Doron Boltin  et al.

PRESCRIPTION PATTERN OF PROBIOTICS AS AN ADJUVANT THERAPY FOR HELICOBACTER PYLORI ERADICATION: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
PRESCRIPTION PATTERN OF PROBIOTICS AS AN ADJUVANT THERAPY FOR HELICOBACTER PYLORI ERADICATION: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Doron Boltin  et al.

THE ROLE OF PROBIOTICS IN THE EFFECTIVENESS OF TREATMENT AGAINST HELICOBACTER PYLORI: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
THE ROLE OF PROBIOTICS IN THE EFFECTIVENESS OF TREATMENT AGAINST HELICOBACTER PYLORI: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Doron Boltin  et al.

IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Doron Boltin  et al.

TRENDS IN THE PRESCRIPTION OF EMPIRICAL TREATMENTS AND THEIR EFFECTIVENESS IN NAÏVE PATIENTS OVER 10 YEARS (2013-2022) IN EUROPE: DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
TRENDS IN THE PRESCRIPTION OF EMPIRICAL TREATMENTS AND THEIR EFFECTIVENESS IN NAÏVE PATIENTS OVER 10 YEARS (2013-2022) IN EUROPE: DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Doron Boltin  et al.

CLINICAL PHENOTYPES THROUGH MACHINE LEARNING OF FIRST-LINE TREATED PATIENTS DURING THE PERIOD 2013-2022: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
CLINICAL PHENOTYPES THROUGH MACHINE LEARNING OF FIRST-LINE TREATED PATIENTS DURING THE PERIOD 2013-2022: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Doron Boltin  et al.

EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 6,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 6,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Doron Boltin  et al.

Item 1 - 15 / 15
1